Expert Interview
A Second View: Delving into the MARINA Phase 1/2 clinical trial data on Avidity Biosciences' AOC 1001 in treating Myotonic Dystrophy
Ticker(s): RNAInstitution: University of Washington
- Associate Professor of Neurology at University of Washington and a researcher at the Seattle Wellstone Center.
- Manages ~15 patients with myotonic dystrophy type 1 (DM1).
- Researches focuses on inclusion body myositis, facioscapulohumeral muscular dystrophy, and ALS (funded throug the NIH), and clinical interests focus on neuromuscular disorders, such as motor neuron disease (ALS), myasthenia gravis, peripheral neuropathies and muscular dystrophies including FSHD.
What is the current standard of care for patients with Myotonic Dystrophy Type 1?
Added By: max_adminOn a scale of 1 to 10, how excited are you about AOC 1001 based on this most recent data?
Added By: max_adminAre there other treatments currently in development for Myotonic Dystrophy which excite you and how do they compare to AOC 1001?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
